Vertex Pharmaceuticals stock
VRTXNASDAQVertex Pharmaceuticals Incorporated, HealthcareISIN US92532F1003
76Score 76 out of 100, Strong
Price and trend
86 / 100
Price history
+27% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 2.1% below its 52-week high. Largest decline in 20 years: 64% (September 2007 to March 2008).
Chart figures for advanced users
- SMA 50$523.04
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$482.70
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$421.03
- The lowest closing price of the last twelve months.
- Resistance$558.88
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Vertex Pharmaceuticals Incorporated belongs to the Biotechnology industry (United States) and, with a market value of $138.69B, is the largest of 296 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $13.25B (up 9.8%) and adjusted earnings per share of $18.23 (down 1%).
- MEQIRI Score 76 out of 100 (Strong): rank 62 of 714 in Healthcare, median 53.
Show more
- The P/E is 35.1 (Biotechnology median 21.3, own median of recent years 26.6).
- Our model puts fair value at $416.67, with the price 31% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 30.6% over the last 12 months, Biotechnology median −93.3%.Profitability 93
- High return on capitalReturn on invested capital 29% in fiscal 2025, Biotechnology median −24.3%.Profitability 93
Weaknesses
- Richly valuedP/E 35.1, Biotechnology median 21.3, own median 26.6.Valuation 33
Its standout strengths are profitability and momentum, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- price near its 52-week high
- solid fundamentals
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $320.52 and expensive above $595.24 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $501.65 (cash-flow model) and $331.69 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $374.82, at 8.4% it would be $477.05.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.8% on the twelve months before. Revenue has grown strongly since 2006, at around 24% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 85%, operating 39%, net 33%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 2 Nov 2026EPS reported $4.76 (expected $4.82)in line with expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 4.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $18.23−2.4%
- Revenue
- $13.25B0.0%
- Earnings per share
- $20.16−4.2%
- Revenue
- $14.68B+0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +0.3%2026 total revenue guidance raised to $13.1 billion to $13.2 billion; non-GAAP operating expense guidance of $5.65 billion to $5.75 billion reiterated, now expected at the high end.
“Given our strong first half performance and the momentum across the business, we are raising our full year 2026 total revenue guidance to a range of $13.1 billion to $13.2 billion, 2026 revenue guidance reflects continued strong performance from the CF franchise, including ALYFTREK and TRIKAFTA as well as growing …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $13.2M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kewalramani ReshmaSale
6 Nov 2026, CEO & President
- Shares
- 11,866
- Price
- $531.53
- Value
- $6.31M
- Tatsis OuraniaSale
2 Jul 2026, EVP, Chief Reg. & Quality Off.
- Shares
- 1,500
- Price
- $524.99
- Value
- $787,485
- McKechnie DuncanSale
2 Jul 2026, EVP, Chief Commercial Officer
- Shares
- 1,541
- Price
- $519.00
- Value
- $799,779
Show 8 more
- Liu JoySale
1 Jul 2026, EVP and Chief Legal Officer
- Shares
- 828
- Price
- $502.71
- Value
- $416,244
- Bozic CarmenSale
26 Jun 2026, EVP and CMO
- Shares
- 596
- Price
- $482.50
- Value
- $287,570
- Bozic CarmenSale
18 Jun 2026, EVP and CMO
- Shares
- 1,020
- Price
- $462.17
- Value
- $471,413
- Bozic CarmenSale
15 Jun 2026, EVP and CMO
- Shares
- 4,062
- Price
- $450.00
- Value
- $1.83M
- Bozic CarmenSale
5 Jun 2026, EVP and CMO
- Shares
- 1,745
- Price
- $450.00
- Value
- $785,250
- Bozic CarmenSale
29 May 2026, EVP and CMO
- Shares
- 1,974
- Price
- $450.00
- Value
- $888,300
- Bunnage Mark E.Sale
15 May 2026, EVP, Chief Scientific Officer
- Shares
- 33
- Price
- $453.45
- Value
- $14,964
- Bozic CarmenSale
15 May 2026, EVP and CMO
- Shares
- 1,354
- Price
- $453.45
- Value
- $613,971
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Vertex Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next smaller companies by market value
- ModernaMRNA $100.63B48
- Regeneron PharmaceuticalsREGN $99.23B81
- UCBUCB.BR $61.8B78
- argenxARGX $61.25B70
- Lonza GroupLONN.SW $55.85B63
- Samsung Biologics207940.KS $49.8B68
- BeOne MedicinesONC $44.88B70
- Revolution MedicinesRVMD $39.08B43
ETFs that hold Vertex Pharmaceuticals
Held by 143 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 7.98% | 0.35% | €1.21B |
| Global X Genomics & Biotechnology UCITS ETFGN0M | 3.45% | 0.50% | €127.06M |
| L&G Pharma Breakthrough UCITS ETFETLI | 2.51% | 0.49% | €26.29M |
Show 5 more
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 2.05% | 0.15% | €592.11M |
| UBS Factor MSCI USA Quality Screened UCITS ETF hEUR accUBUX | 2.02% | 0.28% | €1.14B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 2.02% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 2.02% | 0.15% | €3.27B |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.90% | 0.49% | €318.39M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 8 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.